Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$11.4M | -$31.8M | -$31.2M | -$45.9M | -$56.8M | -$66.7M | -$76.2M | -$49.3M | -$16.2M | -$2.43M |
| Net income | -$12.7M | -$31.3M | -$30.7M | -$46.4M | -$60.0M | -$66.4M | -$77.5M | -$51.6M | -$15.8M | -$1.92M |
| EPS (diluted) | -$1.15 | -$1.24 | -$1.14 | -$1.29 | -$1.14 | -$0.76 | -$10.09 | -$299.95 | -$38.57 | -$0.39 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.13M | -$12.9M | -$19.2M | -$33.6M | -$37.3M | -$53.7M | -$65.1M | -$49.5M | -$11.4M | -$5.26M |
| Capital expenditures | — | $424K | $6.87M | $2.35M | $1.93M | $3.99M | $2.71M | $64.0K | $0.00 | — |
| Free cash flow | — | -$13.4M | -$26.1M | -$35.9M | -$39.2M | -$57.7M | -$67.8M | -$49.5M | -$11.4M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27.5M | $35.5M | $16.5M | $61.4M | $97.8M | $110M | $75.7M | $6.23M | $6.84M | $17.3M |
| Total assets | $27.5M | $63.5M | $42.8M | $73.4M | $110M | $125M | $92.4M | $17.7M | $9.31M | $17.6M |
| Total liabilities | $3.22M | $3.66M | $6.36M | $21.8M | $11.5M | $12.8M | $46.1M | $17.6M | $13.2M | $8.06M |
| Shareholders' equity | $24.3M | $59.8M | $36.4M | $51.7M | $98.4M | $112M | $46.3M | $123K | -$3.87M | $9.53M |
| Retained earnings | -$17.1M | -$48.4M | -$79.1M | -$125M | -$185M | -$252M | -$329M | -$381M | -$397M | -$399M |
| Shares (wtd avg diluted) | 15.2M | 25.2M | 26.6M | 39.4M | 70.9M | 87.9M | 7.68M | 172K | 610K | 4.91M |
Every figure is extracted from MUSTANG BIO, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.